PMID- 32398700
OWN - NLM
STAT- MEDLINE
DCOM- 20201130
LR  - 20210512
IS  - 2045-2322 (Electronic)
IS  - 2045-2322 (Linking)
VI  - 10
IP  - 1
DP  - 2020 May 12
TI  - Clinical efficacy of Stereotactic Body Radiation Therapy (SBRT) for adrenal gland 
      metastases: A multi-center retrospective study from China.
PG  - 7836
LID - 10.1038/s41598-020-64770-2 [doi]
LID - 7836
AB  - To evaluate the efficacy and safety of CyberKnife Stereotactic Body Radiation 
      Therapy (SBRT) in the treatment of adrenal gland metastases (AGM), we designed a 
      large-scale multicenter retrospective study to report the safety and efficacy of 
      SBRT for inoperable AGM. In this study, 75 (61 males, 14 females) patients with 
      84 AGM and Karnofsky performance score >/=70 were treated by SBRT from October 2006 
      to January 2017. Of these, the purpose of treatment were controlling all known 
      metastatic sites for 21 patients while 54 for palliation of bulky adrenal 
      metastases. The efficacy and safety of SBRT were evaluated during follow-up. 
      Potential factors predictive of local control (LC) and overall survival (OS) were 
      identified by univariate and multivariate analysis. Median follow-up time was 
      12.7 months (range 1.8-96.4). The complete response (CR), partial response (PR), 
      stable disease (SD) and progressive disease (PD) rates were 23.8%, 23.8%, 31.0% 
      and 21.4%, respectively. The 0.5, 1, and 2-year LC rates were 93.6%, 83.8%, and 
      62.1%, respectively; OS rates on the same follow-up intervals were 93.7%, 62.5%, 
      and 49.6%, respectively, and the corresponding PFS rates were 48.5%, 33.9%, and 
      16.0%, respectively. The treatment was well tolerated with 2 patients reporting 
      grade-3 diarrhea and fatigue, respectively. Multivariate analysis showed that 
      simultaneous treatment of SBRT for other metastatic lesions, the number of AGM, 
      initiation of systemic therapy, and the maximum diameter of AGM were predictive 
      of LC rates. Moreover, patients with AGM < 5 cm had a superior OS compared with 
      those with AGM >/= 5 cm (28.0 months vs. 17.6 months, P = 0.032). SBRT is an 
      effective therapeutic option for treatment of AGM with high LC rates with minimal 
      toxicity.
FAU - Zhao, Xianzhi
AU  - Zhao X
AD  - Department of Radiation Oncology, Shanghai Changhai Hospital, Naval Medical 
      University, Shanghai, 200433, China.
FAU - Zhu, Xiaofei
AU  - Zhu X
AD  - Department of Radiation Oncology, Shanghai Changhai Hospital, Naval Medical 
      University, Shanghai, 200433, China.
FAU - Zhuang, Hongqing
AU  - Zhuang H
AD  - Department of Radiation Oncology, Peking University Third Hospital, Beijing, 
      100191, China.
FAU - Guo, Xueling
AU  - Guo X
AD  - Department of Radiation Oncology, Shanghai Changhai Hospital, Naval Medical 
      University, Shanghai, 200433, China.
FAU - Song, Yongchun
AU  - Song Y
AD  - Department of Radiation Oncology and CyberKnife Center, Key Laboratory of Cancer 
      Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin 
      Medical University Cancer Institute and Hospital, National Clinical Research 
      Center for Cancer, Tianjin, 300060, China.
FAU - Ju, Xiaoping
AU  - Ju X
AD  - Department of Radiation Oncology, Shanghai Changhai Hospital, Naval Medical 
      University, Shanghai, 200433, China.
FAU - Wang, Ping
AU  - Wang P
AD  - Department of Radiation Oncology and CyberKnife Center, Key Laboratory of Cancer 
      Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin 
      Medical University Cancer Institute and Hospital, National Clinical Research 
      Center for Cancer, Tianjin, 300060, China.
FAU - Yuan, Zhiyong
AU  - Yuan Z
AD  - Department of Radiation Oncology and CyberKnife Center, Key Laboratory of Cancer 
      Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin 
      Medical University Cancer Institute and Hospital, National Clinical Research 
      Center for Cancer, Tianjin, 300060, China. zhiyong0524@163.com.
FAU - Zhang, Huojun
AU  - Zhang H
AD  - Department of Radiation Oncology, Shanghai Changhai Hospital, Naval Medical 
      University, Shanghai, 200433, China. chyyzhj@163.com.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20200512
PL  - England
TA  - Sci Rep
JT  - Scientific reports
JID - 101563288
SB  - IM
MH  - Adrenal Gland Neoplasms/*radiotherapy/*secondary
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Radiosurgery/adverse effects
MH  - Retrospective Studies
MH  - Safety
MH  - Treatment Outcome
PMC - PMC7217854
COIS- The authors declare no competing interests.
EDAT- 2020/05/14 06:00
MHDA- 2020/12/01 06:00
PMCR- 2020/05/12
CRDT- 2020/05/14 06:00
PHST- 2018/06/28 00:00 [received]
PHST- 2020/01/24 00:00 [accepted]
PHST- 2020/05/14 06:00 [entrez]
PHST- 2020/05/14 06:00 [pubmed]
PHST- 2020/12/01 06:00 [medline]
PHST- 2020/05/12 00:00 [pmc-release]
AID - 10.1038/s41598-020-64770-2 [pii]
AID - 64770 [pii]
AID - 10.1038/s41598-020-64770-2 [doi]
PST - epublish
SO  - Sci Rep. 2020 May 12;10(1):7836. doi: 10.1038/s41598-020-64770-2.